Journal Article

DKFZ-2024-02255

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance.

Sobas, M. A. ; Turki, A. T. ; Ramiro, A. V. ; Sánchez, A. H. ; Elicegui, J. M. ; González, T. ; Melchor, R. A. ; Abáigar, M. ; Tur, L. ; Dall'Olio, D. ; Sträng, E. ; Tettero, J. M. ; Castellani, G. ; Benner, A.DKFZ* ; Döhner, K. ; Thiede, C. ; Metzeler, K. H. ; Haferlach, T. ; Damm, F.DKFZ* ; Ayala, R. ; Martínez-López, J. ; Mills, K. I. ; Sierra, J. ; Lehmann, S. ; Porta, M. G. D. ; Mayer, J. ; Reinhardt, D. ; Medina, R. V. ; Schulze-Rath, R. ; Barbus, M. ; Hernández-Rivas, J. M. ; Huntly, B. J. P. ; Ossenkoppele, G. ; Döhner, H. ; Bullinger, L.DKFZ*

2025
Ferrata Storti Foundation Pavia

This record in other databases:  

Please use a persistent id in citations: doi:10.3324/haematol.2024.285805

Abstract: Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcome of patients with acute myeloid leukemia (AML). However, even before these innovations outcomes with intensive chemotherapy have improved, which has not yet been extensively studied. Thus, we used a large pan-European multicenter dataset of the HARMONY Alliance to evaluate treatment-time dependent outcomes over two decades. In 5359 AML patients, we compared the impact of intensive induction therapy on outcome over four consecutive 5-year calendar periods from 1997 to 2016. During that time, the 5- year survival of AML patients improved significantly, also across different genetic risk groups. In particular, the 60-day mortality rate has dropped from 13.0% to 4.7% over time. The independent effect of calendar periods on outcome was confirmed in multivariate models. Improvements were documented both for patients.

Note: 2025 May 1;110(5):1126-1140

---

Contributing Institute(s):

1. C060 Biostatistik (C060)
2. DKTK Koordinierungsstelle Berlin (BE01)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2024

---

Database coverage:
; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DOAJ Seal ; Essential Science Indicators ; Fees ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---